Doxorubicin hydrochloride is approved for use with other drugs as adjuvant therapy for breast cancer that has spread to the lymph nodes, including cancer that is HER-2 positive or has spread after surgery.
In addition to the uses that have been approved by the FDA, doxorubicin hydrochloride is sometimes used alone or with other drugs to treat other types of cancer. The drug continues to be studied in the treatment of many types of cancer.
Cancer treatment is hard on the body, however for the patient to endure cancer, it is mostly necessary to undergo the treatment.
A team of researchers described an innovative nanofluidic device for high-throughput preparation of exosome-based drug delivery vehicles.
A new study has shown that it is viable to reduce tumor growth by a therapy that involves tagging cancer cells with various therapeutic molecules.
With the evolution of cancer, the quest for identifying efficient treatment techniques for cancer patients has remained challenging.
Current chemotherapy regimens slow cancer progression and save lives, but these powerful drugs affect both healthy and cancerous cells.
Multidrug resistance, or MDR, is a process in which tumors become impervious to numerous drugs and is a major cause of failure in cancer chemotherapy.
Researchers have unraveled a crucial factor that governs whether malignant cells will develop into a tumor. The study was recently published in the eLife journal.
Researchers at the University of Arkansas have developed a new nano drug candidate that kills triple negative breast cancer cells.
The p53 gene is crucial in cell biology and thus cell replacement therapy. The function of this gene is to control the cell cycle and stop tumor formation.
For many years, researchers have analyzed the use of liposomes, which are hollow spheres composed of lipid bilayers, to transmit chemotherapy drugs to tumor cells.